MedTrace Logo

Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts

NCT02752893 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-06-01

No results posted yet for this study

Summary

The investigators will establish a platform at Dartmouth-Hitchcock Medical Center to generate novel models of estrogen receptor alpha-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which will be used for research studies to develop novel treatment strategies and dissect signaling pathways underlying drug sensitivity and resistance.

Conditions

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-30
Primary Completion
2019-04-03
Completion
2019-04-03

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02752893 on ClinicalTrials.gov